Keywords: EuropaBio, Value of innovation, Access to novel drugs

Globalize the evidence, standardize the decisions, says EuropaBio on assessing the value of innovation and improving access to novel drugs

Article | 07 May 2010

The European biotechnology trade group EuropaBio hosted a high-level workshop on Health Technology Assessment (HTA) at the International BIO Conference ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in